PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline. Paul Hudson, CEO of Sanofi said, "The proposed acquisition of Blueprint Medicines ...
Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, ...
Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...
Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer-healthcare arm ...
Kate Haviland is CEO of Blueprint Medicines. From the Boston Business Journal. Sanofi is acquiring Blueprint Medicines Corp. and its rare immunology disease treatment, which is already approved in the ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback